---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105953"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:43:02.742309+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma Q3 net loss $7.5M; cash $35.4M; NXP900 Phase 1b underway

## Summary
- Cash $35.4M at Sep 30, 2025, up from $18.5M at Dec 31, 2024; runway into 3Q2027.
- Net loss $7.5M (Q3 2025) vs $4.2M (Q3 2024); increase driven by $2.0M NXP900 milestone expense.
- R&D expenses $5.8M (Q3 2025) vs $2.8M (Q3 2024), reflecting clinical progress.
- NXP900 Phase 1b single-agent portion initiated; combination arm expected by year-end 2025.
- Phase 1a dose escalation and drug-drug interaction study completed with pharmacodynamic responses at clinically relevant doses.

## SEC filing metadata
- accession: 0001104659-25-105953
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465925105953/0001104659-25-105953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465925105953/tm2530070d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105953
- JSON: https://secwatch.observer/filing/0001104659-25-105953.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.